SINGAPORE, Singapore, 7 June 2022 – MiRXES, a Singapore-based biotechnology company focused on early, actionable, and personalized diagnoses, announced a strategic partnership with MGI, a leading developer of high-throughput sequencing, to advance spatio-temporal transcriptomics and multi-omics research in human development and disease.
The collaboration will integrate MiRXES’s RNA translational research and molecular diagnostics capabilities with MGI’s DNBSEQ-T10×4RS* sequencing system, creating an ultra-high-throughput, high-resolution spatial genomics platform in Singapore. Housed in MiRXES’s purpose-built multi-omics laboratory at Biopolis, it will be the first facility of its kind in the Asia-Pacific region outside China. The platform will enable collaborations with academic and clinical institutions globally and provide researchers with access to cutting-edge capabilities for biomarker discovery, disease pathway analysis, and targeted drug development.
“Spatial multi-omics is one of the most exciting fields in biological and clinical research. This partnership naturally extends MiRXES’s clinical biomarker research to understand the origin and dynamics of disease biomarkers,” said Dr Lihan Zhou, Co-founder and CEO of MiRXES.
Dr Zhou added, “Our partnership with MGI strengthens multi-omics research capabilities and opens new horizons for biomarker discovery, early disease detection, and precision medicine in Singapore and the regional biomedical ecosystem. MGI’s DNBSEQ-T10×4RS* system is key to high-resolution multi-omics research with unparalleled cost-effectiveness. To support this, MiRXES has welcomed Dr Holger Heyn, a spatial transcriptomics expert from CNAG, to our Scientific Advisory Board.”
Dr Roy Tan, General Manager of MGI APAC, commented: “We are proud to collaborate with MiRXES to build this pioneering end-to-end platform in Singapore, a scientific hub in ethnically diverse Southeast Asia. The DNBSEQ-T10×4RS* system will increase sequencing throughput, lower costs, and accelerate spatial multi-omics, epi-genomics, and single-cell genomics research to advance preventive and precision healthcare.”
*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria, and Romania.
About MiRXES
Founded in 2014 as a spin-off from Singapore’s Agency for Science, Technology and Research (A*STAR), MiRXES develops RNA-powered tests for early disease detection, with pipelines across multiple cancers, cardiovascular, metabolic, and infectious diseases. Headquartered in Singapore, MiRXES operates in the United States, China, and Japan, with commercial activities in over 45 countries. In 2019, MiRXES launched GASTROClear, the world’s first microRNA blood test for early gastric cancer detection. Its multi-cancer, multi-omics early detection pipeline includes screening for lung, colorectal, liver, breast, pancreatic, and ovarian cancers. For more information, visit www.mirxes.com
